1st Feb 2006 12:12
1 February 2006Application has been made to the UK Listing Authority and the London StockExchange for a listing of 600,000 ordinary shares of 5p each in the Company tobe admitted to the Official List.These shares, ranking pari passu in all respects with the existing shares inissue, have been issued pursuant to the exchange of certain Exchangeable Sharesin Shire Acquisition Inc., in accordance with the terms of the Merger Agreementwith BioChem Pharma Inc.T MayCompany SecretaryFor further information please contact:Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsSHIRE PLCShire's strategic goal is to become the leading specialty pharmaceuticalcompany that focuses on meeting the needs of the specialist physician. Shirefocuses its business on central nervous system (CNS), gastrointestinal (GI),general products (GP) and human genetic therapies (HGT) - all being areas inwhich Shire has a commercial presence. The structure is sufficiently flexibleto allow Shire to target new therapeutic areas to the extent opportunitiesarise through acquisitions. Shire believes that a carefully selected portfolioof products with a strategically aligned and relatively small-scale sales forcewill deliver strong results. Shire's focused strategy is to develop and marketproducts for specialty physicians. This approach aims to deliver increasedreturns and lower risks. Shire's in-licensing and merger and acquisitionefforts are focused on products in niche markets with strong intellectualproperty protection either in the US or Europe.For further information on Shire, please visit the Company's website: www.shire.com. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDSHIRE PLCRelated Shares:
Shire